Porphyria-like Neurological Crises and Fanconi Syndrome-Type Renal Tubular Disorder in An Undiagnosed Case of Chronic Tyrosinemia Type 1: A Case Report and Review of the Literature

Adib, Ehsan; Abbasi, Nima; Salehzadeh, Elina; Ekhlasi, Nahideh

doi:10.22038/jpp.2026.98117.5721

Porphyria-like Neurological Crises and Fanconi Syndrome-Type Renal Tubular Disorder in An Undiagnosed Case of Chronic Tyrosinemia Type 1: A Case Report and Review of the Literature

Document Type : case report

Authors

Ehsan Adib ¹^{, 2}

Nima Abbasi ¹

Elina Salehzadeh ¹

Nahideh Ekhlasi ³

¹ Students Research Committee, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran.

² Cancer Immunology and Immunotherapy Research Center, Ardabil University of Medical Sciences, Ardabil, Iran.

³ Pediatric Department of Bou Ali Hospital, Ardabil University of Medical Sciences, Ardabil, Iran.

10.22038/jpp.2026.98117.5721

Abstract

Background: Tyrosinemia type 1 (TYRSN1) is an autosomal recessive metabolic disease that occurs due to a defect in the enzyme fumarylacetoacetate hydroxylase. In the case of a defect in this enzyme, toxic metabolites resulting from the breakdown of tyrosine accumulate in vital organs, leading to various symptoms and problems in these patients.
Case Presentation: A 3-year-old boy was admitted to the hospital with confusion, constipation, vomiting, abdominal pain, fever, oliguria, and anorexia. On examination, hypertension, genu varum, abnormal gait, and urinary retention were observed. Laboratory tests revealed hypoglycemia, glucosuria, metabolic acidosis, anemia, hypokalemia, and hypocalcemia. Ultrasound and CT scans revealed large kidneys and a heterogeneous liver, with multiple nodules. Additional tests revealed elevated alkaline phosphatase, a high alpha-fetoprotein level, hypophosphatemia, and increased urinary excretion of phosphorus and potassium. Hand radiography also revealed rickets. Due to suspicion of hereditary diseases of amino acid metabolism, blood and urine chromatography revealed a marked accumulation of tyrosine. The diagnosis of chronic TYRSN1 was confirmed by measuring high urinary excretion of succinylacetone. The patient was treated with nitisinone and a restricted diet of tyrosine and phenylalanine, and within 1 week, he showed a dramatic response to treatment.
Conclusion: Our patient was a case of chronic TYRSN1 who, owing to a lack of timely diagnosis, had symptoms of neurological crises similar to acute porphyria, as well as symptoms of Fanconi syndrome-type renal tubular disorder and rickets. Due to the rarity of this disease and its diverse clinical manifestations, its diagnosis is challenging in countries such as Iran, where screening for this disease is not routinely

Keywords

Fumarylacetoacetate deficiency

Neurological crises

Tyrosinemia type 1

1. Scott CR. The genetic tyrosinemias. InAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics 2006 May 15 (Vol. 142, No. 2, pp. 121-126). Hoboken: Wiley Subscription Services, Inc., A Wiley Company.

2. Cassiman D, Zeevaert R, Holme E, Kvittingen EA, Jaeken J. A novel mutation causing mild, atypical fumarylacetoacetase deficiency (Tyrosinemia type I): a case report. Orphanet journal of rare diseases. 2009 Dec 15;4(1):28.

3. Lindblad B, Lindstedt S, Steen GO. On the enzymic defects in hereditary tyrosinemia. Proceedings of the National Academy of Sciences. 1977 Oct;74(10):4641-5.

4. Chen J, Sun J, Li X, Du M. Identification and functional characterization of a novel homozygous intronic variant in the fumarylacetoacetate hydrolase gene in a Chinese patient with tyrosinemia type 1. BMC Medical Genomics. 2022 Dec 3;15(1):251.

5. Angileri F, Bergeron A, Morrow G, Lettre F, Gray G, Hutchin T, et al. Geographical and ethnic distribution of mutations of the fumarylacetoacetate hydrolase gene in hereditary tyrosinemia type 1. InJIMD Reports, Volume 19 2015 Feb 15 (pp. 43-58). Berlin, Heidelberg: Springer Berlin Heidelberg.

6. Chinsky JM, Singh R, Ficicioglu C, Van Karnebeek CD, Grompe M, Mitchell G, et al. Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations. Genetics in Medicine. 2017 Dec;19(12):1380-.

7. Rokaitė R, Čibirkaitė A, Zeleckytė V, Lazdinytė G, Dženkaitis M. A Lithuanian Case of Tyrosinemia Type 1 with a Literature Review: A Rare Cause of Acute Liver Failure in Childhood. Medicina. 2024 Jan 11;60(1):135.

8. Morrow G, Tanguay RM. Biochemical and clinical aspects of hereditary tyrosinemia type 1. InHereditary Tyrosinemia: Pathogenesis, screening and management 2017 Jul 29 (pp. 9-21). Cham: Springer International Publishing.

9. Grompe M, Al-Dhalimy M, Finegold M, Ou CN, Burlingame T, Kennaway NG, et al. Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice. Genes & development. 1993 Dec 1;7(12a):2298-307.

10. King LS, Trahms C, Scott CR. Tyrosinemia type I. InGeneReviews®[Internet] 2017 May 25. University of Washington, Seattle.

11. González-Lamuño D, Sánchez-Pintos P, Andrade F, Couce ML, Aldámiz-Echevarría L. Treatment adherence in tyrosinemia type 1 patients. Orphanet Journal of Rare Diseases. 2021 Jun 3;16(1):256.

12. Van Spronsen FJ, Thomasse Y, Smit GP, Leonard JV, Clayton PT, Fidler V, et al. Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment. Hepatology. 1994 Nov;20(5):1187-91.

13. De Laet C, Dionisi-Vici C, Leonard JV, McKiernan P, Mitchell G, Monti L, et al. Recommendations for the management of tyrosinaemia type 1. Orphanet journal of rare diseases. 2013 Jan 11;8(1):8.

14. Kawabata K, Kido J, Yoshida T, Matsumoto S, Nakamura K. A case report of two siblings with hypertyrosinemia type 1 presenting with hepatic disease with different onset time and severity. Molecular Genetics and Metabolism Reports. 2022 Sep 1;32:100892.

15. Prabhakar S, Banu N, Srinivas M. Tyrosinemia type 1: A case report. Indian Journal of Child Health. 2014 Dec;1:155-7.

16. Thomas H, Carlisle RC. Progress in gene therapy for hereditary tyrosinemia type 1. Pharmaceutics. 2025 Mar 18;17(3):387.

17. Mitchell G, Larochelle J, Lambert M, Michaud J, Grenier A, Ogier H, et al. Neurologic crises in hereditary tyrosinemia. New England Journal of Medicine. 1990 Feb 15;322(7):432-7.

18. Dawson C, Ramachandran R, Safdar S, Murphy E, Swayne O, Katz J, et al. Severe neurological crisis in adult patients with Tyrosinemia type 1. Annals of clinical and translational neurology. 2020 Sep;7(9):1732-7.

19. Önenli Mungan N, Yıldızdaş D, Kör D, Horoz ÖÖ, İncecik F, Öktem M, et al. Tyrosinemia type 1 and irreversible neurologic crisis after one month discontinuation of nitisone. Metabolic brain disease. 2016 Oct;31(5):1181-3.

20. van Ginkel WG, Jahja R, Huijbregts SC, van Spronsen FJ. Neurological and neuropsychological problems in tyrosinemia type I patients. Hereditary Tyrosinemia: Pathogenesis, Screening and Management. 2017 Jul 29:111-22.

21. Larochelle J, Alvarez F, Bussières JF, Chevalier I, Dallaire L, Dubois J, et al. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec. Molecular genetics and metabolism. 2012 Sep 1;107(1-2):49-54.

22. Sun MS, Hattori S, Kubo S, Awata H, Matsuda I, Endo F. A Mouse Model of Renal Tubular Injury of Tyrosinemia Type 1: Development of de Toni Fanconi Syndrome and Apoptosis of Renal Tubular Cells in: Fah/Hpd: Double Mutant Mice. Journal of the American Society of Nephrology. 2000 Feb 1;11(2):291-300.

23. van Ginkel WG, van Vliet D, van Der Goot E, Faassen MH, Vogel A, Heiner-Fokkema MR, et al. Blood and brain biochemistry and behaviour in NTBC and dietary treated tyrosinemia type 1 mice. Nutrients. 2019 Oct 16;11(10):2486.

24. Forget S, Patriquin HB, Dubois J, Lafortune M, Merouani A, Paradis K, et al. The kidney in children with tyrosinemia: sonographic, CT and biochemical findings. Pediatric radiology. 1999 Jan;29(2):104-8.

25. van Ginkel WG, Rodenburg IL, Harding CO, Hollak CE, Heiner-Fokkema MR, van Spronsen FJ. Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1: WG Ginkel et al. Pediatric Drugs. 2019 Dec;21(6):413-26.

26. Ilyaz M, Jadhav RS, Pande V, Mane S, Mokkarala P. Hereditary tyrosinemia type-1 with late presentation: a case report. Cureus. 2024 Jun 23;16(6).

27. Paradis K, D'Angata ID, Bijleveld C, Bueller H, Taminiau J, Thomas A, et al. Nephropathy of Tyrosinemia and its longterm outlook. Journal of Pediatric Gastroenterology and Nutrition. 1997 Jan;24(1):113-4.

28. Croffie JM, Gupta SK, Chong SK, Fitzgerald JF. Tyrosinemia type 1 should be suspected in infants with severe coagulopathy even in the absence of other signs of liver failure. Pediatrics. 1999 Mar 1;103(3):675-8.

29. Herbst DA, Reddy KR. Risk factors for hepatocellular carcinoma. Clinical liver disease. 2013 Jan 23;1(6):180.

30. Matpathi A. A rare case report of tyrosinemia type I. South Asian Journal of Health Sciences. 2023 Dec 28;1:47-50.

31. Lindstedt MS, Holme ME, Lock PE, Hjalmarson MO, Strandvik MB. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. The Lancet. 1992 Oct 3;340(8823):813-7.

32. Introne WJ. Nitisinone: Two decades treating hereditary tyrosinaemia type 1. The Lancet Diabetes & Endocrinology. 2021 Jul 1;9(7):409-11.

33. Aharbil F, Jarti M, Nacir O, Lairani F, Ait Errami A, Samlani Z, et al. Teenage Girl with Tyrosinemia Type 1 Masquerading as Hepatic Insufficiency: A Rare Case Report. Sch J Med Case Rep. 2024;5:908-10.

34. Schlune A, Thimm E, Herebian D, Spiekerkoetter U. Single dose NTBC-treatment of hereditary tyrosinemia type I. Journal of inherited metabolic disease. 2012 Sep;35(5):831-6.

35. Mayorandan S, Meyer U, Gokcay G, Segarra NG, de Baulny HO, van Spronsen F, et al. Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice. Orphanet journal of rare diseases. 2014 Aug 1;9(1):107.

36. Äärelä L, Hiltunen P, Soini T, Vuorela N, Huhtala H, Nevalainen PI, et al. Type 1 tyrosinemia in Finland: A nationwide study. Orphanet journal of rare diseases. 2020 Oct 12;15(1):281.

37. van Ginkel WG, Jahja R, Huijbregts SC, Daly A, MacDonald A, De Laet C, et al. Neurocognitive outcome in tyrosinemia type 1 patients compared to healthy controls. Orphanet journal of rare diseases. 2016 Jun 29;11(1):87.

38. García MI, de la Parra A, Arias C, Arredondo M, Cabello JF. Long-term cognitive functioning in individuals with tyrosinemia type 1 treated with nitisinone and protein-restricted diet. Molecular genetics and metabolism reports. 2017 Jun 1;11:12-6.

39. Bendadi F, De Koning TJ, Visser G, Prinsen HC, De Sain MG, Verhoeven-Duif N, et al. Impaired cognitive functioning in patients with tyrosinemia type I receiving nitisinone. The Journal of Pediatrics. 2014 Feb 1;164(2):398-401.

40. Malik S, NiMhurchadha S, Jackson C, Eliasson L, Weinman J, Roche S, et al. Treatment adherence in type 1 hereditary tyrosinaemia (HT1): a mixed-method investigation into the beliefs, attitudes and behaviour of adolescent patients, their families and their health-care team. InJIMD Reports, Volume 18 2014 Sep 12 (pp. 13-22). Berlin, Heidelberg: Springer Berlin Heidelberg.

41. Yue TA, Yuanyuan KO. Hereditary tyrosinemia type Ⅰ: newborn screening, diagnosis and treatment. Journal of Zhejiang University (Medical Sciences). 2021 Aug;50(4):514.

42. Bartlett DC, Lloyd C, McKiernan PJ, Newsome PN. Early nitisinone treatment reduces the need for liver transplantation in children with tyrosinaemia type 1 and improves post‐transplant renal function. Journal of Inherited Metabolic Disease: Official Journal of the Society for the Study of Inborn Errors of Metabolism. 2014 Sep;37(5):745-52.